Company intelligence / Profile preview
ScandiBio Therapeutics
Stockholm, Swedenscandibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ScandiBio Therapeutics demonstrated positive clinical outcomes with metabolic cofactor supplementation, including reduced recovery time in mild-to-moderate COVID-19 patients and ongoing Phase 3 trials in Alzheimer's disease[4].
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small moleculeCombination therapy (metabolic cofactor supplementation)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
KTH Royal Institute of TechnologyKarolinska InstitutetSahlgrenska Academy[1]King's College London (COVID-19 clinical study)[4]
Beyond the preview
Go deeper on ScandiBio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ScandiBio Therapeutics.